Form 8-K - Current report:
SEC Accession No. 0001193125-25-128680
Filing Date
2025-05-28
Accepted
2025-05-28 07:12:40
Documents
13
Period of Report
2025-05-28
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d903768d8k.htm   iXBRL 8-K 29600
2 EX-99.1 d903768dex991.htm EX-99.1 23593
  Complete submission text file 0001193125-25-128680.txt   177147

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA spro-20250528.xsd EX-101.SCH 2868
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE spro-20250528_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE spro-20250528_pre.xml EX-101.PRE 11273
15 EXTRACTED XBRL INSTANCE DOCUMENT d903768d8k_htm.xml XML 3635
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38266 | Film No.: 25991141
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)